Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Safety and efficacy of intramuscular human placenta-derived mesenchymal stromal-like cells (cenplacel [PDA-002]) in patients who have a diabetic foot ulcer with peripheral arterial disease.

Wu SC, Pollak R, Frykberg RG, Zhou W, Karnoub M, Jankovic V, Fischkoff SA, Chitkara D.

Int Wound J. 2017 Oct;14(5):823-829. doi: 10.1111/iwj.12715. Epub 2017 Jan 30.

PMID:
28133924
2.

Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.

Lublin FD, Bowen JD, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy JR, Freedman MS, Krupp L, Paulo C, Hariri RJ, Fischkoff SA.

Mult Scler Relat Disord. 2014 Nov;3(6):696-704. doi: 10.1016/j.msard.2014.08.002. Epub 2014 Aug 29.

3.

Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: a phase 1 study.

Mayer L, Pandak WM, Melmed GY, Hanauer SB, Johnson K, Payne D, Faleck H, Hariri RJ, Fischkoff SA.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):754-60. doi: 10.1097/MIB.0b013e31827f27df.

5.
6.

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

Clin Ther. 2003 Jun;25(6):1700-21.

PMID:
12860493
7.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK.

Arthritis Rheum. 2003 Jan;48(1):35-45. Erratum in: Arthritis Rheum. 2003 Mar;48(3):855.

8.

Leukocyte chemotactic activity of cyclophilin.

Xu Q, Leiva MC, Fischkoff SA, Handschumacher RE, Lyttle CR.

J Biol Chem. 1992 Jun 15;267(17):11968-71.

9.

Glucocorticoid and progestin regulation of eosinophil chemotactic factor and complement C3 in the estrogen-treated rat uterus.

Howe RS, Lee YH, Fischkoff SA, Teuscher C, Lyttle CR.

Endocrinology. 1990 Jun;126(6):3193-9.

PMID:
2351113
10.

Chemotactic capabilities of HL-60 human myeloid leukemia cells differentiated to eosinophils.

Howe RS, Fischkoff SA, Rossi RM, Lyttle CR.

Exp Hematol. 1990 May;18(4):299-303.

PMID:
2323365
11.
13.

Factors responsible for variable reported lineages of HL-60 cells induced to mature with butyric acid.

Hoessly MC, Rossi RM, Fischkoff SA.

Cancer Res. 1989 Jul 1;49(13):3594-7.

14.

Acute eosinophilic leukemia with a (10;11) chromosomal translocation.

Fischkoff SA, Testa JR, Schiffer CA.

Leukemia. 1988 Jun;2(6):394-7.

PMID:
3374171
16.

Induction of differentiation of the human leukemia cell line, KU812.

Fischkoff SA, Kishi K, Benjamin WR, Rossi RM, Hoessly MC, Hoxie JA, Seals C, Anderson L, Ishizaka T, Hakimi J.

Leuk Res. 1987;11(12):1105-13.

PMID:
3695564
17.

Synthesis of eosinophil-associated enzymes in HL-60 promyelocytic leukemia cells.

Fischkoff SA, Brown GE, Pollak A.

Blood. 1986 Jul;68(1):185-92.

19.

Development of membrane-potential responsiveness by myeloid leukemia cells during neutrophilic differentiation.

Brown GE, Fischkoff SA, Ordonez JV.

Biochem Biophys Res Commun. 1984 Sep 28;123(3):937-43.

PMID:
6593070
20.

Eosinophilic differentiation of the human promyelocytic leukemia cell line, HL-60.

Fischkoff SA, Pollak A, Gleich GJ, Testa JR, Misawa S, Reber TJ.

J Exp Med. 1984 Jul 1;160(1):179-96.

22.
23.

Cell surface membrane protein changes during the differentiation of cultured human promyelocytic leukemia HL-60 cells.

Felsted RL, Gupta SK, Glover CJ, Fischkoff SA, Gallagher RE.

Cancer Res. 1983 Jun;43(6):2754-61.

24.

Supplemental Content

Loading ...
Support Center